SELLAS Life Sciences Group, Inc. Common Stock
XNAS:SLS
1.8
$1.80 - 100.00
$1.76 - 800.00
$1.69
$1.8
$1.72
$1.74
2.48
0.77
4275560
4115579.6
142004703.06
Chart
TendieTensor AI Analysis
Company
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Fundamentals
15
-6.060000
4.769610
-0.06
100
BBG000VC77H7
BBG001T223C9
105.30M
147.44M
Technicals
Short Interest
—
—
—
Higher = harder to cover
—
Prev: —
—
—
5D avg: —
—
Discussion
Login to participate in discussions.
Recent News
Related Stocks
Based on the portfolios of people who own SLS. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.